Literature DB >> 6732268

Vitamin E treatment of haemolytic uraemic syndrome.

H R Powell, D A McCredie, C M Taylor, J R Burke, R G Walker.   

Abstract

Because low plasma vitamin E concentrations have been reported in patients with haemolytic uraemic syndrome and there is accumulating evidence of lipid peroxidation in this disease, treatment with the antioxidant vitamin E was undertaken in 16 consecutive children with the syndrome. Twelve children had features at presentation suggesting a poor prognosis for recovery but despite this all 16 patients survived and are well three months later. Fifteen children now have normal values for serum creatinine, blood pressure, and urinalysis for protein but one has slight renal impairment. Although this is not a report of a controlled trial, it seems that patients treated with vitamin E have fared considerably better than our previously treated patients with haemolytic uraemic syndrome, even in the presence of early, adverse prognostic features. We suggest that vitamin E alters the natural history of the disease, and in view of the absence of any observed side effects further experience with this treatment is being sought.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732268      PMCID: PMC1628506          DOI: 10.1136/adc.59.5.401

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  15 in total

Review 1.  Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis.

Authors:  S Moncada; J R Vane
Journal:  Br Med Bull       Date:  1978-05       Impact factor: 4.291

2.  The treatment of the hemolytic-uremic syndrome with inhibitors of platelet function.

Authors:  C A Thorsen; E C Rossi; D Green; F A Carone
Journal:  Am J Med       Date:  1979-04       Impact factor: 4.965

3.  Has heparin changed the prognosis of the hemolytic-uremic syndrome.

Authors:  W Proesmans; R Eeckels
Journal:  Clin Nephrol       Date:  1974 Sep-Oct       Impact factor: 0.975

4.  Streptokinase and anti-thrombotic therapy in the hemolytic-uremic syndrome.

Authors:  H R Powell; H Ekert
Journal:  J Pediatr       Date:  1974-03       Impact factor: 4.406

5.  The hemolytic-uremic syndrome in California: a review of 28 nonheparinized cases with long-term follow-up.

Authors:  B M Tune; T J Leavitt; T J Gribble
Journal:  J Pediatr       Date:  1973-02       Impact factor: 4.406

6.  Vitamin E. An inhibitor of the platelet release reaction.

Authors:  M Steiner; J Anastasi
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

7.  A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation.

Authors:  S Moncada; R J Gryglewski; S Bunting; J R Vane
Journal:  Prostaglandins       Date:  1976-11

8.  Treatment of the hemolytic uremic syndrome with plasma.

Authors:  G Remuzzi; R Misiani; D Marchesi; M Livio; G Mecca; G de Gaetano; M D Donati
Journal:  Clin Nephrol       Date:  1979-12       Impact factor: 0.975

9.  Red cell membrane phospholipid abnormalities in the hemolytic uremic syndrome.

Authors:  S O'Regan; R W Chesney; B S Kaplan; K N Drummond
Journal:  Clin Nephrol       Date:  1981-01       Impact factor: 0.975

10.  Generation of prostacyclin-like substance and lipid peroxidation in vitamin E-deficient rats.

Authors:  M Okuma; H Takayama; H Uchino
Journal:  Prostaglandins       Date:  1980-04
View more
  6 in total

1.  Haemolysis in childhood.

Authors:  B Holland; C A Wardrop
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

Review 2.  Hemolytic uremic syndrome.

Authors:  B R Nammalwar; N Balasubramanian; C Thangadurai; B R Santhanakrishnan
Journal:  Indian J Pediatr       Date:  1987 Sep-Oct       Impact factor: 1.967

Review 3.  Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Ramon Alfonso Exeni; Romina Jimena Fernandez-Brando; Adriana Patricia Santiago; Gabriela Alejandra Fiorentino; Andrea Mariana Exeni; Maria Victoria Ramos; Marina Sandra Palermo
Journal:  Pediatr Nephrol       Date:  2018-01-25       Impact factor: 3.714

Review 4.  Prostacyclin in diarrhoea-associated haemolytic uraemic syndrome.

Authors:  C M Taylor; C J Lote
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

5.  Further evidence of lipid peroxidation in post-enteropathic haemolytic-uraemic syndrome.

Authors:  R D Situnayake; B J Crump; D I Thurnham; C M Taylor
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

6.  Oxidative damage of red blood cells in haemolytic uraemic syndrome.

Authors:  S Túri; I Németh; I Vargha; B Matkovics
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.